Expectations Of Lumakras ESMO Late-Breaker Build As Roche Plays KRAS Catch-Up
Conference Kicks Off On 9 September
Amgen secured a last-minute slot as a late-breaker study with Lumakras, appearing to give it the upper hand on rival Mirati once again.
You may also be interested in...
Roche Goes Big On KRAS-Mutated Cancers In Hookipa Pact
Deal Snapshot: The Nobel Prize winner co-founded biotech can extend its cash runway into 2025, while Roche gains access to an immunotherapy with potential to treat a wide range of cancers.
Roche Plays Down Reliance On TIGIT And Alzheimer’s Drugs For Growth
Pharma chief Bill Anderson was optimistic about growth prospects, and downplayed Roche’s reliance on two near-term readouts at an investor day in London.
Amgen’s Lumakras Succeeds In Confirmatory Lung Cancer Trial
Amgen said its KRAS G12C inhibitor Lumakras (sotorasib) bested docetaxel in a Phase III clinical trial on the primary endpoint of progression-free survival in second-line-plus non-small cell lung cancer.